The Comparative Oncology Program of the University of California, Davis Cancer Center focuses on several specific aspects of cancer biology in animals. The first major theme, Tumor Biology, is the study of major Oncogenes, Tumor Suppressor genes. Cancer Stem Cells and Inflammation-Cancer. The second major theme. Genetically Defined Animal Models of Cancer, is the study of tumor development and progression employing transgenic and knockout animal models to elucidate basic mechanisms. The third major theme, Spontaneous Cancers in Large Animals, uses non-rodent animals to study tumor development and invesfigate novel diagnosfics and therapeufics in a preclinical setfing. This program brings a unique combinafion of skills and models to the preclinical setfing. It provides the critical links between bench and bedside. The programmatic goals are: (1) to examine the signaling pathways of oncogenes and tumor suppressor genes and the role of inflammation and cancer stem cells in tumorigenesis using both in vitro systems and genefically defined animal models of cancer in vivo; (2) to characterize genefically induced tumorigenesis in animal models and development of novel animal models and experimental approaches; (3) to characterize spontaneous cancers in large animals and to perform preclinical evaluation of novel diagnostics and therapeutics; and (4) collaboration with other programs to facilitate translational research. The program has 29 members from ten different departments and three schools at UC Davis. It has 17 NClfunded projects for $2.6 million ADC (total peer-reviewed funding, $11.4 million ADC). The group has 524 publications for the last funding period; 21% are inter-programmafic and 10% are intra-programmafic.

Public Health Relevance

This program moves the discovery of new therapies for cancer by taking fundamental cancer discoveries and modeling them in mice. In addifion, the program is unique in having 1300 patients (dogs and cats) that present with cancer to the veterinary school each year. By working together with colleagues treating human pafients, the hope is to bring othenwise not available therapies to our veterinary pafients, while speeding the discovery for new and effective therapies for our human patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA093373-10S3
Application #
8567365
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$48,858
Indirect Cost
$17,132
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91

Showing the most recent 10 out of 836 publications